Arcellx

Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.

Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.

Arcellx headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Pharmaceutical, Biopharma sector. The company focuses on Biotechnology and has secured $87.1B in funding across 140 round(s). With a team of 101-250 employees, Arcellx is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Arcellx, raised $200.0M. Discover more about their projects, partnerships, and impact on our platform.